Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets
This article was originally published in PharmAsia News
MUMBAI - Merck & Co. is establishing a joint venture with India's Sun Pharmaceutical Industries Ltd. for a broad-based alliance to develop, manufacture and commercialize novel combinations and "incrementally innovative" branded generics in emerging markets, the two companies announced April 11
You may also be interested in...
Lupin, Merck KGaA In Advanced Talks For Complex Generics Deal
Changing landscape of the global pharmaceutical market is likely bringing India’s Lupin and German’s Merck closer. Industry sources say a deal is close to being announced.
India’s SPARC Scouts For Allies As Pipeline Drugs Advance, Higher Expenses Lurk
Sun Pharma Advanced Research Company (SPARC) briefed analysts about its pipeline of drugs under development. While candidates seem to have showed positive results, SPARC will eye partnering prospects to enrich and grow its pipeline.
Sun Pharmaceutical’s SPARC Unit Hopes To Kindle India Research Pipeline
Sun Pharma’s research unit SPARC shared an update of its research pipeline, but analysts are short on excitement, owing mostly to delays on timelines.